Company profile for TransThera Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Nanjing TransThera Biosciences Co. Ltd. is an innovation platform company focused on discovery and development of small molecule new drugs. Our research and business strategies zero in clear unmet medical needs in oncology and inflammatory diseases through internal research and open innovation. We have competent management team and highly experienced science team. Bearing a mission to deliver transformative therapies to global...
Nanjing TransThera Biosciences Co. Ltd. is an innovation platform company focused on discovery and development of small molecule new drugs. Our research and business strategies zero in clear unmet medical needs in oncology and inflammatory diseases through internal research and open innovation. We have competent management team and highly experienced science team. Bearing a mission to deliver transformative therapies to global patients, we have established an R&D engine with multi-disciplines that enables us to continuously innovate.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Floor 3, Building 9, Phase 2 Accelerator, Biopharma Valley, Jiangbei New Area,...
Telephone
Telephone
025-86901057
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/neurocrine-pens-880m-deal-chinas-transthera-red-hot-immunology-target

FIERCE BIOTECH
04 Nov 2025

https://www.prnewswire.com/news-releases/2024-ashtransthera-announces-the-phase-i-study-results-of-tt-01488-a-novel-non-covalent-btk-inhibitor--in-patients-with-relapsed-or-refractory-b-cell-malignancies-302326854.html

PR NEWSWIRE
10 Dec 2024

https://www.prnewswire.com/news-releases/2024-esmo-asia-transthera-announces-clinical-data-of-tinengotinib-in-combination-with-atezolizumab-pd-l1-in-biliary-tract-carcinoma-btc-302325654.html

PR NEWSWIRE
09 Dec 2024

https://www.prnewswire.com/news-releases/transthera-announced-global-phase-3-clinical-trial-for-cholangiocarcinoma-authorized-in-the-european-union-and-orphan-drug-designation-for-tinengotinib-to-treat-biliary-tract-cancer-granted-by-european-medicines-agency-302084086.html

PR NEWSWIRE
08 Mar 2024

https://www.prnewswire.com/news-releases/transthera-initiates-ind-enabling-studies-for-tt-02332-a-novel-highly-potent-and-cns-penetrating-nlrp3-inhibitor-302070999.html

PR NEWSWIRE
26 Feb 2024

https://www.prnewswire.com/news-releases/transthera-announces-the-global-multicenter-phase-3-clinical-trial-completed-first-patient-dosing-in-the-us-evaluating-tinengotinib-in-fgfri-relapsedrefractory-patients-with-cholangiocarcinoma-302021004.html

PR NEWSWIRE
21 Dec 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty